The device has evolved from one aimed at just functional MR to a broader HF therapy. EMPOWER will provide more insights.

The revolutionary BiVACOR heart device was moved to Phase 2 of FDA trials after success in five human patients.

High-volume centres achieve excellent long-term survival and low reoperation rates in mitral valve repair—key findings ...

February is American Heart Month, so I felt it was finally time to share my personal heart story. My paternal line has a long ...